Atopic dermatitis (eczema) trials in Spain

In Spain 20 Also abroad 251

20 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Where
Alicante, Fuenlabrada, Madrid, Valencia
Age
6 months to 11 years
People
195 worldwide
Run by
LEO Pharma
See details and how to joinNCT06311682 · EU 2023-503630-44-00
Phase 3Not yet taking people in Spain
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Where
Alicante, Badalona, Bilbao, Las Palmas De Gran Canaria, Madrid, Santiago de Compostela
People
150 worldwide
Run by
Hunan Mabgeek Biotech Co. Ltd.
See details and how to join2025-525022-35-00 · EU 2025-525022-35-00
Phase 3Taking people
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Where
Granollers, Santiago de Compostela, Zaragoza
Age
2 years to 11 years
People
450 worldwide
Run by
Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00
Phase 2Taking people
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Where
Alicante, Badalona, Las Palmas de Gran Canaria, Madrid, Santiago de Compostela
Age
18 years and over
People
350 worldwide
Run by
Apogee Therapeutics, Inc.
See details and how to joinNCT07003425
No phaseTaking people
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Where
Alicante, Barcelona, Santa Cruz de Tenerife
Age
12 years and over
People
1,000 worldwide
Run by
Sanofi
See details and how to joinNCT07290803
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
Where
Alicante, Badalona, Madrid, Santiago de Compostela, Zaragoza
Age
18 years and over
People
138 worldwide
Run by
Apollo Therapeutics Limited
See details and how to join2026-525673-39-00 · EU 2026-525673-39-00
Phase 3Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Barcelona, Las Palmas de Gran Canaria, Madrid, Manises, Pamplona, Pontevedra, Pozuelo de Alarcón
Age
6 months to 18 years
People
338 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Alicante, Bilbao, Burjassot, Granada, Madrid, Málaga, Sevilla, Valencia
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07690371 · EU 2025-524925-42-00
Phase 3Not yet taking people in Spain
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Where
Alicante, Badalona, Barcelona, Bilbao, Granada, Granollers, Las Palmas De Gran Canaria, L'hospitalet De Llobregat, Madrid, Majadahonda, Málaga, Palma, Pontevedra, Salamanca, Santiago de Compostela, Sevilla, Valencia, Zaragoza
Age
12 years and over
People
230 worldwide
Run by
Almirall, S.A.
See details and how to joinNCT07873801 · EU 2025-525133-31-00
Phase 2Not yet taking people in Spain
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
Where
Alicante, Madrid, Santiago de Compostela
Age
18 years and over
People
96 worldwide
Run by
Enveda Therapeutics Inc.
See details and how to join2026-526184-38-00 · EU 2026-526184-38-00
Phase 2Taking people
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Where
Alicante, Badalona, Granada, Las Palmas De Gran Canaria, Madrid, Pontevedra
Age
18 years to 100 years
People
224 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00
Phase 3Taking people
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Where
Granollers, Santiago de Compostela, Zaragoza
Age
6 years to 11 years
People
150 worldwide
Run by
Pfizer
See details and how to joinNCT06807268 · EU 2023-509121-51-00
Phase 1Taking people
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
Where
Barcelona
Age
18 years to 64 years
People
291 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2025-523826-41-00 · EU 2025-523826-41-00
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Where
Alicante, Badalona, La Paz, Santiago de Compostela, Zaragoza
Age
18 years to 65 years
People
280 worldwide
Run by
Apollo Therapeutics Ltd
See details and how to joinNCT07599813
Phase 2Taking people
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
Where
Alicante, Badalona, Las Palmas De Gran Canaria, Madrid, Santiago de Compostela
Age
18 years and over
People
175 worldwide
Run by
Apogee Therapeutics Inc.
See details and how to join2024-519795-11-00 · EU 2024-519795-11-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Where
Barcelona, Córdoba, Granollers, Las Palmas De Gran Canaria, L'hospitalet De Llobregat, Madrid, Manises, Santiago de Compostela, Zaragoza
Age
18 years to 74 years
People
405 worldwide
Run by
Inmagene LLC
See details and how to joinNCT07037901 · EU 2024-520117-50-00
No phaseTaking people
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
Where
A Coruña, Almería, Barcelona, Madrid, Málaga, Seville, Tarragona, Zaragoza
Age
1 day to 14 days
People
400 worldwide
Run by
Société des Produits Nestlé (SPN)
See details and how to joinNCT06943469
Phase 2Taking people
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Where
Alicante, Burjassot, Granada, Málaga, Manises, Mieres, Sevilla
Age
18 years and over
People
200 worldwide
Run by
Corvus Pharmaceuticals, Inc.
See details and how to joinNCT07441395 · EU 2025-524384-20-00
Phase 4Taking people
Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II)
Where
Madrid
Run by
Hospital Universitario La Paz
See details and how to join2023-506165-62-00 · EU 2023-506165-62-00
No phaseTaking people
Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy
Where
Alicante, Badalona, Barcelona, Las Palmas, Madrid, Pontevedra, Valencia, Zaragoza
People
2,500
Run by
Fundación Academia Española de Dermatología
See details and how to joinNCT05674695